{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T12:10:11Z","timestamp":1735042211322,"version":"3.32.0"},"reference-count":32,"publisher":"Termedia Sp. z.o.o.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To identify the most effective treatment for juvenile dermatomyositis (JDM), considering efficacy, safety, impact on patients and improvement in their quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>A systematic review was carried out comparing known treatments and immunobiological therapies, evaluating clinical improvement, adverse events and prognosis. The MEDLINE, PubMed, LILACS and Cochrane Library databases were used with children aged 0 to 18 diagnosed with JDM. The PRISMA 2020 statement was followed throughout the process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The immunobiologics studied were rituximab (RTX) and anti-tumor necrosis factor drugs and used the Disease Activity Score to skin, Childhood Myositis Assessment Scale and Manual Muscle Testing tools. There was no difference in the response when RTX was used (early or late). The anti-TNF studies were carried out in a population that was refractory to the initial treatment and showed a significant improvement in muscle and skin disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For severe or refractory disease, biologics tend to be the medication with the best therapeutic response.<\/jats:p><\/jats:sec>","DOI":"10.5114\/reum\/195799","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T11:43:21Z","timestamp":1735040601000},"page":"447-455","source":"Crossref","is-referenced-by-count":0,"title":["Immunobiologics in juvenile dermatomyositis: a systematic review of promising therapeutic advances"],"prefix":"10.5114","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-9931","authenticated-orcid":true,"given":"Aline Maria de Oliveira","family":"Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-045X","authenticated-orcid":false,"given":"Gabriel Fidelis","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3909-607X","authenticated-orcid":false,"given":"Juliana Capecce","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"ref-1342089","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-"},{"key":"ref-1342090","doi-asserted-by":"publisher","DOI":"10.2174\/15733.96317666210426105045"},{"key":"ref-1342091","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-020-00168-5"},{"key":"ref-1342092","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0467-y"},{"key":"ref-1342093","doi-asserted-by":"crossref","unstructured":"Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors asso\u00adciated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84: 68\u201374.","DOI":"10.1590\/S0021-75572008000100012"},{"key":"ref-1342094","doi-asserted-by":"crossref","unstructured":"Clemente G, Piotto DGP, Barbosa C, et al. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study. Rev Bras Reumatol (Press) 2012; 52: 545\u2013553.","DOI":"10.1590\/S0482-50042012000400007"},{"key":"ref-1342095","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000220"},{"key":"ref-1342096","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, et al. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al. (eds.). Cochrane Handbook for Systema\u00adtic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available at: www.training.cochrane. org\/handbook."},{"key":"ref-1342097","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00313-8"},{"key":"ref-1342098","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"ref-1342099","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref-1342100","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (eds.). GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available at: guidelinedevelopment.org\/handbook."},{"key":"ref-1342101","doi-asserted-by":"publisher","DOI":"10.1002\/art.30475"},{"key":"ref-1342102","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab089"},{"key":"ref-1342103","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-282x2002000600001"},{"key":"ref-1342104","doi-asserted-by":"publisher","DOI":"10.1177\/088307389801300303"},{"key":"ref-1342105","unstructured":"Chowdhary V, Wakhlu A, Agarwal A, Misra R. Outcome in juvenile dermatomyositis. Indian Pediatrics 2002; 39: 931\u2013935."},{"key":"ref-1342106","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"ref-1342107","doi-asserted-by":"publisher","DOI":"10.1002\/art.38270"},{"key":"ref-1342108","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101321"},{"key":"ref-1342109","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02164-5"},{"key":"ref-1342110","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken074"},{"key":"ref-1342111","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00785-5"},{"key":"ref-1342112","doi-asserted-by":"publisher","DOI":"10.1002\/acr"},{"key":"ref-1342113","doi-asserted-by":"publisher","DOI":"10.1136\/adc.72.1.25"},{"key":"ref-1342114","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3530-4"},{"key":"ref-1342115","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0326-5"},{"key":"ref-1342116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1377952"},{"key":"ref-1342117","doi-asserted-by":"publisher","DOI":"10.1002\/art.23829"},{"key":"ref-1342118","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90010-u"},{"key":"ref-1342119","doi-asserted-by":"publisher","DOI":"10.3109\/14397595"},{"key":"ref-1342120","doi-asserted-by":"publisher","DOI":"10.1542\/peds"}],"container-title":["Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-195799-119829","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-195799-119829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T11:44:06Z","timestamp":1735040646000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Immunobiologics-in-juvenile-dermatomyositis-a-systematic-review-of-promising-therapeutic,195799,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"alternative-id":["195799"],"URL":"https:\/\/doi.org\/10.5114\/reum\/195799","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]}}}